Introduction: Spinal anesthesia is a common anesthetic technique for lower limb and abdominal surgery. Despite its efficacy, its use is limited because of its duration and potential severe side effects, especially in high-risk patients undergoing major surgery. Adjuvants such as dexamethasone offer the potential to prolong the anesthetic effect and reduce the need for local anesthetics while reducing the incidence of serious adverse events. The purpose of this systematic review is to evaluate the efficacy of dexamethasone as an intrathecal adjuvant in prolonging anesthetic duration, delaying pain onset, and minimizing adverse events (PROSPERO registration: CRD42022350218).

Evidence Acquisition: We included randomized controlled trials conducted in adult patients undergoing spinal anesthesia for lower limb or abdominal surgery and comparing the performance of dexamethasone with alternative spinal treatments. A comprehensive systematic search was conducted on PubMed/MEDLINE, Scopus, CINAHL, EMBASE, CENTRAL, and Cochrane Library from February to June 2023 without language restriction. Risk of bias was assessed using the Cochrane Risk of Bias Tool (RoB2).

Evidence Synthesis: Ten studies, nine of which were at high risk of bias, were included (N.=685 patients). Overall, intrathecal dexamethasone was associated with a longer duration of sensory block, improvement in the duration or extent of postoperative analgesia, and significant shortening of block onset. The role of dexamethasone in prolonging motor block was not clear. The incidence of adverse events was low. Intrathecal dexamethasone has been shown to be a potentially valuable adjuvant to prolong the duration of sensory block and improve postoperative analgesia without increasing adverse events.

Conclusions: Given the wide heterogeneity of methodological approaches, further investigation is needed. Considering the limitations of the included studies and awaiting more conclusive evidence, the prudent use of dexamethasone could be recommended in those specific situations where general anesthesia or higher local anesthetics should be avoided.

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0375-9393.24.18054-6DOI Listing

Publication Analysis

Top Keywords

intrathecal dexamethasone
12
spinal anesthesia
12
adverse events
12
risk bias
12
systematic review
8
lower limb
8
limb abdominal
8
abdominal surgery
8
patients undergoing
8
local anesthetics
8

Similar Publications

Several adjuvant drugs have been tried to prolong spinal anesthesia block. Currently, dexamethasone appears to be effective in extending the duration of sensory block and enhancing analgesia during surgery. It is unclear, however, whether administering dexamethasone at a dose of 8 mg offers any advantages over administering it at a dose of 4 mg.

View Article and Find Full Text PDF
Article Synopsis
  • - The study examined 9 patients with Systemic Lupus Erythematosus (SLE) who also had Guillain-Barré syndrome (GBS) or chronic inflammatory demyelinating polyradiculoneuritis (CIDP), analyzing their clinical characteristics and outcomes over a 17-year period.
  • - Among the patients, 6 had SLE with GBS and 3 had SLE with CIDP, with common symptoms including limb weakness and neurological issues like dysphagia and facial nerve palsy.
  • - Treatments included glucocorticoids, immunoglobulin therapy, and other immunosuppressants, leading to varied outcomes, highlighting the importance of proper diagnosis and treatment approaches in SLE-related
View Article and Find Full Text PDF

Background: Multiple myeloma (MM) relapse in the central nervous system (CNS) confers an adverse prognosis, usually occurring in a short period after stem cell transplant and with a short overall survival. Isolated CNS relapse is so rare that there is no current standard treatment.

Case Description: We present a 59-year-old male with an isolated CNS MM relapse, who had received autologous stem-cell transplant (ASCT) and thalidomide maintenance 11 years prior.

View Article and Find Full Text PDF
Article Synopsis
  • Methotrexate is a key medication for treating childhood cancers like acute lymphoblastic leukemia but can lead to severe side effects such as neurotoxicity, specifically leukoencephalopathy, which usually presents with gradual neurological symptoms.
  • A case involving a 10-year-old boy showed acute neurological symptoms, including limb weakness and involuntary movements, after taking oral methotrexate, a rare occurrence compared to traditional administration routes like injection.
  • MRI scans revealed brain abnormalities consistent with methotrexate-induced neurotoxicity, highlighting the need for careful monitoring of neurological effects even with oral use of the drug.
View Article and Find Full Text PDF

Earlier intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome.

Int Immunopharmacol

December 2024

Hematology & Oncology, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu, China; Pediatric Intensive Care Unit, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu, China. Electronic address:

Chimeric antigen receptor T cell (CAR-T) therapy is effective in treating relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the side effects of immune effector cell-associated neurotoxicity syndrome (ICANS) remain a problem. The current frontline therapies for ICANS include steroids and supportive care.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!